Alpha-Synuclein Test: How It Works and What It Detects

Alpha-synuclein tests detect misfolded clumps of a brain protein called alpha-synuclein, and their primary purpose is to identify Parkinson’s disease and related conditions years earlier and more accurately than clinical observation alone. The most widely used version, known as a seed amplification assay, works by taking a tiny sample of body fluid or tissue and coaxing any abnormal protein present to multiply in a lab dish until it becomes measurable. Across multiple sample types, these assays have demonstrated sensitivity and specificity figures approaching or exceeding 90% for Parkinson’s disease, which represents a major shift in how neurologists think about diagnosis. But the story gets more interesting when you look at which conditions the test catches, which it sometimes misses, and how the choice of sample changes the picture.

What Alpha-Synuclein Is and Why Misfolding Matters

Alpha-synuclein is a small, abundant protein found at the junctions where nerve cells communicate. In its healthy state, it has no fixed three-dimensional shape and is thought to play a role in how brain cells release signaling chemicals.¹ The trouble starts when copies of the protein misfold and stick together into clumps. These aggregates are believed to be a critical step in Parkinson’s disease and several related neurological conditions.² The hallmark pathological structures in Parkinson’s, known as Lewy bodies and Lewy neurites, are composed primarily of alpha-synuclein that has deposited in an aggregated fibril state.¹

What makes misfolded alpha-synuclein especially dangerous is that it appears to act like a seed: once a few copies go wrong, they recruit neighboring normal copies to misfold as well, spreading the damage through the nervous system. That seeding behavior is also what makes the test possible. If you can provide the right conditions in a test tube, even a trace amount of misfolded protein will trigger a chain reaction that amplifies the signal enough to detect.

How Seed Amplification Assays Work

The core concept behind these tests is straightforward, even if the lab work is precise. A sample, whether it is spinal fluid, a skin biopsy, or blood, is mixed with a large supply of normal, healthy alpha-synuclein protein and a fluorescent dye that glows when it binds to the fibril structures formed by misfolded protein. The mixture is then subjected to cycles of shaking and resting. The shaking breaks growing fibrils into smaller fragments, creating more “seeds.” During the rest periods, those seeds recruit normal protein to misfold and extend. Over many cycles, any misfolded alpha-synuclein originally present in the sample gets amplified billions of times over, producing a fluorescence signal the lab can measure.

Two main versions of this technology exist. One, called RT-QuIC (real-time quaking-induced conversion), uses vigorous shaking. The other, PMCA (protein misfolding cyclic amplification), uses sonication, essentially blasting the mixture with ultrasound waves. Both achieve the same goal of amplifying trace seeds into a detectable signal. The differences between them matter for researchers trying to distinguish between disease subtypes, but from a patient’s perspective, both are ways of asking the same question: is misfolded alpha-synuclein present in this sample?

What the Test Detects

Alpha-synuclein seed amplification assays are designed to detect a family of conditions collectively called synucleinopathies, all of which involve the abnormal accumulation of misfolded alpha-synuclein. The main conditions in this family are Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.

The test performs best for Parkinson’s disease and dementia with Lewy bodies. A systematic review and meta-analysis of CSF-based assays found diagnostic sensitivity and specificity of about 91% and 96% for Lewy body disease.³ A more recent network meta-analysis across all sample types placed overall sensitivity at about 86% and specificity at 92%.⁴ These are strong numbers for a biological test in neurology, a field where diagnoses have historically relied almost entirely on a clinician’s judgment of symptoms.

Multiple system atrophy is trickier. The same meta-analysis of CSF assays found sensitivity dropped to about 63% for MSA, while specificity remained very high at 97%.³ The reason likely relates to the fact that MSA involves a different “strain” of misfolded alpha-synuclein, one that behaves differently in the amplification assay. Researchers have found that by modifying the chemical conditions of the assay, specifically the buffer solution used, they can tailor the reaction to pick up MSA-derived seeds more reliably.⁵ A multicenter comparison confirmed this: one buffer formulation detected seeds in MSA, while another was highly specific for Parkinson’s disease and dementia with Lewy bodies but missed MSA entirely.⁶

Telling Synucleinopathies Apart

Detecting misfolded alpha-synuclein is one thing; telling clinicians which disease it represents is another. Here the assays offer a surprising level of nuance. When researchers compared spinal fluid samples from people with Parkinson’s or dementia with Lewy bodies against samples from MSA patients, the misfolded protein amplified with noticeably different timing and intensity. All the Parkinson’s and nearly all the Lewy body dementia samples were positive, but the aggregation happened later and reached a higher peak fluorescence. MSA samples, by contrast, aggregated earlier but plateaued at a lower signal, allowing near-perfect separation between the two groups.⁷ This kinetic fingerprinting reflects the different structural “strains” of misfolded protein underlying each condition and could eventually replace the clinical guesswork that currently distinguishes them.

Which Samples Can Be Tested

One of the most active areas of research is figuring out which body samples work best. The earliest and most validated approach uses cerebrospinal fluid obtained through a lumbar puncture, commonly known as a spinal tap. CSF assays deliver the highest and most consistent accuracy figures. But lumbar puncture is invasive, uncomfortable for many patients, and occasionally causes headaches lasting several days. In one study comparing skin biopsy and CSF sampling, about 17% of patients who underwent lumbar puncture developed headaches significant enough to need days of pain medication.⁸

Skin biopsy has emerged as a strong and less invasive alternative. Misfolded alpha-synuclein deposits in the tiny nerve fibers that innervate sweat glands and hair follicles, and a small punch biopsy can pick them up. A large multicenter study found that skin biopsy detected phosphorylated alpha-synuclein in about 93% of people with confirmed Parkinson’s, 98% with MSA, and 96% with dementia with Lewy bodies, while fewer than 4% of healthy controls tested positive.⁹ Earlier work had already shown that skin biopsies provide better than 90% sensitivity and specificity for distinguishing Parkinson’s from healthy controls across different biopsy sites.¹⁰ When skin and CSF results are compared head-to-head, agreement between the two approaches is very high, around 99% in one study of people with isolated REM sleep behavior disorder.¹¹

A uniform seeding amplification assay tested across multiple tissue types confirmed the strong match between CSF and skin, with skin reaching 94% sensitivity and 98% specificity against CSF-positive dementia with Lewy bodies patients and healthy controls. The same study, however, found much lower sensitivity for olfactory mucosa (47%) and urine (22%), and alpha-synuclein was undetectable in saliva altogether.¹² Olfactory sampling via nasal brushing is painless and well tolerated, but its sensitivity currently hovers around 50% for Parkinson’s patients and about two-thirds for people with isolated REM sleep behavior disorder, depending on which side of the nasal cavity is sampled.¹³ More work is needed to improve these less invasive routes, but nasal swabs may eventually serve as a quick screening tool even if they cannot match the accuracy of CSF or skin.

Blood-Based Testing

The ultimate goal for many researchers is a simple blood draw. Blood-based seed amplification assays are still in early development, but the results so far are tantalizing. In one retrospective study, researchers analyzed stored blood samples from people who were later diagnosed with Parkinson’s. All of those patients showed a positive alpha-synuclein seeding signal in blood samples collected one to ten years before their clinical diagnosis.¹⁴ The technique works by isolating tiny membrane-wrapped packages, called extracellular vesicles, that nerve cells shed into the bloodstream. These vesicles carry misfolded alpha-synuclein conformers that can be amplified and detected.¹⁵ The studies are small and not yet ready for clinical use, but they demonstrate the principle that a blood test for prodromal Parkinson’s is plausible.

Catching Disease Before Symptoms Appear

Perhaps the most consequential application of alpha-synuclein testing is in people who do not yet have an obvious movement disorder. Isolated REM sleep behavior disorder, a condition where people physically act out their dreams during sleep, is now recognized as one of the strongest predictors of future Parkinson’s disease or dementia with Lewy bodies. The vast majority of people with this sleep disorder will eventually develop a full synucleinopathy. Alpha-synuclein seed amplification assays can already detect misfolded protein in many of these individuals, potentially years before motor symptoms emerge.¹⁶ In the CSF-based meta-analysis, prodromal synucleinopathies were detected with about 90% sensitivity and 96% specificity, nearly matching the performance in established disease.³

Pure autonomic failure, another prodromal condition involving blood pressure drops and other autonomic nervous system problems without obvious brain symptoms, also shows robust alpha-synuclein deposits in skin nerve fibers. Studies have found misfolded alpha-synuclein in skin samples from all tested patients with pure autonomic failure, while controls were consistently negative.¹⁷ The pattern of deposition in skin differs between pure autonomic failure and Parkinson’s, suggesting the two conditions involve distinct underlying pathological processes even though both feature alpha-synuclein aggregation.¹⁸

When Genetics Complicate the Picture

Not all Parkinson’s is the same at the molecular level, and genetic background affects how well the test works. People with mutations in the GBA gene, which codes for an enzyme involved in cellular waste disposal, tend to have very high rates of positive seeding. In one study, 93% of Parkinson’s patients carrying severe GBA mutations tested positive, and they showed the strongest amplification signal.¹⁹ People with LRRK2 mutations, another common genetic cause of Parkinson’s, are a different story. Only about 40 to 78% of LRRK2-Parkinson’s carriers show positive seeding.²⁰ This likely reflects the fact that LRRK2-driven Parkinson’s does not always involve the same degree of alpha-synuclein pathology; some of these patients have tau tangles or other pathological features instead of classic Lewy bodies.

The most striking gap is in people who carry two copies of mutations in recessive Parkinson’s genes, such as PRKN or PINK1. In the same study, none of those patients tested positive for alpha-synuclein seeding.¹⁹ These individuals have Parkinson’s that looks clinically similar but is driven by a fundamentally different mechanism, one that does not rely on alpha-synuclein aggregation. For them, a negative test result does not mean they do not have Parkinson’s. It means their version of the disease operates through a different molecular pathway.

Alpha-Synuclein in Alzheimer’s Disease

One of the more surprising findings in recent years is that alpha-synuclein pathology is not limited to the conditions traditionally classified as synucleinopathies. About 30% of people with Alzheimer’s disease test positive on alpha-synuclein seed amplification assays, compared to roughly 9% of healthy controls.²¹ This co-pathology is not benign. Alzheimer’s patients who also harbor misfolded alpha-synuclein show faster accumulation of tau, one of the two core Alzheimer’s proteins, in brain regions typically hit by the disease. They also experience faster cognitive decline, potentially driven by the compounding effect of having two protein aggregation processes running simultaneously.²² This suggests that alpha-synuclein testing could eventually play a role in stratifying Alzheimer’s patients, identifying those likely to deteriorate faster and potentially guiding treatment choices as therapies targeting these proteins become available.

From Lab to Clinic

Alpha-synuclein testing is already making its way into real-world clinical practice. The Syn-One Test, a commercially available skin biopsy test, has been used for nearly 50,000 patients in the United States since its launch in 2019. It employs three small skin punch biopsies to detect phosphorylated alpha-synuclein and assess nerve fiber density. In October 2025, the FDA granted it breakthrough device designation for aiding the diagnosis of synucleinopathies in patients aged 40 and older with suggestive clinical features. On the research side, the FDA endorsed the CSF seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting alpha-synuclein-related diseases, allowing trial designers to enroll participants based on confirmed underlying pathology rather than symptoms alone.²³

Economic data is also emerging. A study of 100 patients with suspected synucleinopathy found that nearly 70% of all tests and specialist referrals were ordered before patients received skin-based alpha-synuclein testing. After the test, the number of MRIs ordered dropped from 89 to 23, and DaTscans dropped from 20 to 6. Annualized neurological healthcare spending for that group fell by about $100,000 per year.²⁴ That pattern makes intuitive sense: when a definitive biological test is available, doctors order fewer exploratory scans and referrals.

Standardization Remains the Big Challenge

For all their promise, these assays are not yet standardized in the way that, say, a blood glucose test is. Different labs use different buffer conditions, different shaking protocols, and different recombinant alpha-synuclein preparations, and these variations can affect results. The multicenter comparison study found that both major assay conditions showed high reproducibility when run at separate laboratories, but they had distinctly different diagnostic profiles: one detected MSA, the other did not.⁶ That is a consequential difference for patients. A neurologist ordering a seed amplification assay for a patient suspected of having MSA needs to know which assay protocol the lab is running, and right now that information is not always transparent.

Another open problem is that the test currently gives a binary answer, positive or negative, rather than a graded measure of disease severity or progression. Researchers can observe differences in the speed and intensity of the amplification reaction between samples, and these kinetic parameters do correlate with genetic subtypes and disease severity in research settings. But translating those subtle kinetic signatures into clinically useful staging or prognosis tools requires much larger validation studies.

The Ethics of Early Detection

The ability to detect alpha-synuclein pathology years before symptoms emerge raises difficult questions that the science alone cannot answer. If you are told at age 55 that misfolded alpha-synuclein has been found in your spinal fluid, but you feel perfectly healthy, what do you do with that information? Studies of people with isolated REM sleep behavior disorder have found that most want to know their prognosis, but individual preferences vary significantly, and the psychological impact of learning you may develop Parkinson’s or dementia is not trivial.²⁵ Right now there is no approved disease-modifying therapy that can halt or slow synucleinopathies once detected, so the practical benefit of very early biological diagnosis is limited to clinical trial enrollment, lifestyle planning, and psychological preparation. As therapies targeting alpha-synuclein aggregation advance through clinical trials, the calculus will shift. The FDA’s endorsement of the assay as a clinical trial biomarker is explicitly aimed at speeding that process along.²³